---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-24-000041"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2024-04-09T23:59:59+00:00"
generated_at: "2026-06-04T00:55:39.146928+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix announces first clinical responses in brain for BTK degrader NX-5948

## Summary
- NX-5948 detected in CSF from all available samples, showing brain penetration.
- CLL patient with CNS involvement achieved partial response by week 24 and cleared tumor cells from CSF.
- PCNSL patient with MYC rearrangement had complete regression of three lesions at week 8, but progressed by week 16.
- Data presented at AACR 2024; NX-5948 is an oral BTK degrader in Phase 1a/1b for B cell malignancies.

## SEC filing metadata
- accession: 0001549595-24-000041
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2024-04-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000041/0001549595-24-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959524000041/nrix-20240409.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-24-000041
- JSON: https://secwatch.observer/filing/0001549595-24-000041.json
- Plain text: https://secwatch.observer/filing/0001549595-24-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.